An announcement from CG Oncology, Inc. ( (CGON) ) is now available.
On April 26, 2025, CG Oncology announced promising results from its Phase 3 BOND-003 clinical trial at the American Urological Association Annual Meeting. The trial data showed a 75.5% complete response rate at any time for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with cretostimogene grenadenorepvec. The 24-month complete response rate was 42.3%, with a median duration of response of 28 months. Additionally, 97.3% of patients remained free from progression to muscle-invasive disease, and the treatment was well-tolerated with no severe adverse events reported. Cohort P also showed a high-grade recurrence-free survival rate of 90.5% at 3 and 9 months. These results position cretostimogene as a potential breakthrough therapy for bladder cancer, offering distinct advantages over existing treatments.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology’s overall stock score reflects significant challenges in financial performance due to ongoing losses and reliance on external funding. However, the company’s strong equity position and recent positive clinical trial results provide potential upside. The technical analysis indicates a bearish trend, and valuation remains a concern with a negative P/E. Investors should be cautious but also consider the potential long-term growth from successful product developments.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative immunotherapies for bladder cancer, aiming to provide bladder-sparing therapeutic options for patients with urologic cancers.
YTD Price Performance: -22.78%
Average Trading Volume: 887,347
Technical Sentiment Signal: Buy
Current Market Cap: $1.7B
Find detailed analytics on CGON stock on TipRanks’ Stock Analysis page.